Experiments with Osimertinib-resistant PC9 and AMG510 insensitive H23 and H358 KRASG12C cells show that CDK9 inhibitors elicit almost identical efficacy on the sensitive and resistant cancer cells. This evidence concerns the gene CDK9 and cancer.